1

2

3

4

5

6

CEFIDEROCOL SULFATE TOSILATE

(CEFIDEROCOLI SULFAS TOSILATUM)

Draft proposal for inclusion in The International Pharmacopoeia

(09 December 2025)

DRAFT FOR COMMENTS

Please submit your comments through the online platform, PleaseReviewTM

https://who.pleasereview.net/Main/Default.aspx?action=loaddocument&reviewid=370

If not registered or included in our mailing list, kindly submit your request with your full name, email address and organization/affiliation to nsp@who.int.

For any technical questions, you may contact Dr Herbert Schmidt, Technical Officer, Norms and Standards for Pharmaceuticals, Technical Standards and Specifications (schmidth@who.int), with a copy to Ms Sinéad Jones (jonessi@who.int, nsp@who.int).

Comments should be submitted through the online platform on or by 09 February 2026. Please note that only comments received by this deadline will be considered for the preparation of this document.

Our working documents are sent out electronically and uploaded into PleaseReview™. The working documents are also placed on the WHO Medicines website (https://www.who.int/teams/health-product-and-policy-standards/standards-andspecifications/pharmaceuticals/working-documents-public-consultation) under the "Working documents in public consultation".

© World Health Organization 2025

All rights reserved.

This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

Please send any request for permission to: Norms and Standards for Pharmaceuticals, Technical Standards and Specifications, Department of Health Products Policy and Standards, World Health Organization, CH-1211 Geneva 27, Switzerland, email: nsp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft.

However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.

36

37 38

39

40

SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/24.967

CEFIDEROCOL SULFATE TOSILATE (CEFIDEROCOLI SULFAS TOSILATUM)

Description	Date
Drafting of the monograph by the Secretariat based on information received from manufacturers and found in the public domain.	July 2024
Draft monograph sent out for public consultation.	July to August 2025
Presentation to the 58 th meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations.	October 2025
Draft monograph sent out for public consultation	December 2025 to February 2026
Further follow-up action as required.	Y

- 41 [Note from the Secretariat. The monograph on Cefiderocol sulfate tosilate is
- 42 proposed for inclusion in The International Pharmacopoeia.
- Being one of the first public standards, the monographs on Cefiderocol sulfate tosilate
- and Cefiderocol powder for concentrate for solution for infusion are expected to play
- 45 an important role in ensuring access to safe, effective and quality-assured essential
- 46 *medicines. Manufacturers, regulatory authorities, procurement agencies and other*
- 47 stakeholders are therefore invited to provide their feedback on the proposed
- 48 specifications and analytical procedures.
- 49 The draft monograph is based on information and samples received from a
- 50 manufacturer, found in the public domain and on laboratory investigations.
- 51 Draft monographs are subject to change.]

CEFIDEROCOL SULFATE TOSILATE

- Molecular formula. $3C_{30}H_{34}ClN_7O_{10}S_2 \cdot 4C_7H_8O_3S \cdot H_2SO_4 \cdot xH_2O$
- Relative molecular mass. 3043.50 (anhydrous cefiderocol sulfate tosilate), 752.21
- 55 (cefiderocol base)

52

57

56 Graphic formula.

- 58 **Chemical names.** Tris[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2- $\{[(2$ -
- 59 carboxypropan-2-yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-
- dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-8-oxo-5-thia-1-
- azabicyclo[4.2.0]oct-2-ene-2-carboxylate] tetrakis(4-methylbenzenesulfonate)
- 62 monosulfate hydrate (*IUPAC*).
- 63 **CAS Registry Number.** 2009350-94-9 (anhydrous substance), 2135543-94-9
- 64 (hydrate)
- **Description.** A white to slightly yellow powder.
- **Solubility.** It is freely soluble in methanol R, slightly soluble in water R and dehydrated
- ethanol R and practically insoluble in acetonitrile R.
- 68 **Category.** Antibacterial (reserve group antibiotic).
- 69 **Storage.** Cefiderocol sulfate tosilate should be kept in tightly closed containers,
- 70 protected from light and below -15 °C.

- 71 **Additional information.** Cefiderocol sulfate tosylate is a mixed salt of cefidericol base
- and two acids, namely 4-toluene sulfonic acid and sulfuric acid. The nominal molar
- ratio of cefiderocol base to 4-toluene sulfonic acid to sulfuric acid in the salt is 3:4:1,
- but the substance may contain an excess of sulfuric acid.
- 75 Cefiderocol sulfate tosylate is hygroscopic, sensitive to hydrolysis and may show
- 76 polymorphism.

77 Requirements

- 78 **Manufacture.** The production method is validated to demonstrate that genotoxic
- 79 impurities of 4-toluenesulfonic acid are adequately controlled in the final product.
- **Definition.** Cefiderocol sulfate tosilate contains not less than 96.0 % and not more than
- 81 104.0% of $3C_{30}H_{34}CIN_7O_{10}S_2\cdot 4C_7H_8O_3S\cdot H_2SO_4$, calculated with reference to the
- anhydrous substance. **Identity tests**
- Either tests A and F, or tests B and F, or any two of tests C, D and E together with test F, may be applied.
- A. Carry out the test as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from cefiderocol sulfate tosilate RS or with the reference spectrum of cefiderocol sulfate tosilate.
- If the spectra thus obtained are not concordant, repeat the test using the residues
- obtained by separately dissolving the test substance and cefiderocol sulfate
- tosilate RS in a small amount of methanol R. Evaporate to dryness and record
- new spectra using the residues. The infrared absorption spectrum is concordant
- with the spectrum obtained from cefiderocol sulfate tosilate RS.
- 94 B. Carry out the test as described under 1.14.1 Chromatography, High-performance
- liquid chromatography, using the conditions given under "Assay" but using, as

the detector, a diode array detector to record the UV spectra of the peaks due to 96 cefiderocol and 4-toluenesulfonic acid in each chromatogram in the range of 210 97 nm to 350 nm and injecting 10 µL of solutions (1) and (2). The retention times 98 and the UV spectra of the peaks due to cefiderocol and 4-toluenesulfonic acid in 99 the chromatogram obtained with solution (1) correspond to the retention times 100 and the UV spectra of the peaks due to cefiderocol and 4-toluenensulfonic acid 101 in the chromatogram obtained with solution (2). 102 C. Carry out the test as described under 1.14.1 Chromatography, High-performance 103 liquid chromatography, using the conditions and solutions given under "Assay". 104 The retention times of the peaks due to cefiderocol and 4-toluenesulfonic acid in 105 the chromatogram obtained with solution (1) correspond to the retention times of 106 the peaks due to cefiderocol and 4-toluenesulfonic acid in the chromatogram 107 108 obtained with solution (2). The absorption spectrum (1.6) of a 0.01 mg per mL solution of the test substance 109 D. in methanol R, when observed between 210 nm and 350 nm, corresponds to the 110 spectrum of cefiderocol sulfate tosilate RS, recorded using the same conditions. 111 Carry out the test as described under 1.14.1 Chromatography, Thin-layer E. 112 chromatography, using silica gel R7 as the coating substance and a freshly 113 prepared mixture of 1 volume of methanol R and 2 volumes of water R as the 114 mobile phase. 115 Apply separately to the plate 10 µL of each of the following four solutions in 116 methanol R. For solution (A), use a solution containing 1.0 mg of the test 117 substance per mL. For solution (B), use a solution containing 20.0 mg of the test 118 119 substance per mL. For solution (C), use a solution containing 1.0 mg of cefiderocol sulfate tosilate RS per mL. For solution (D), use a solution 120 containing 4.5 mg of 4-toluenesulfonic acid R per mL. After removing the plate 121 from the chromatographic chamber, allow it to dry in air, and examine the 122

chromatogram in ultraviolet light (254 nm). 123 The principal spot obtained with solution (A) corresponds in position, 124 appearance and intensity with the spot due to cefiderocol in the chromatogram 125 obtained with solution (C). The spot with an R_F value of about 0.83 obtained 126 with solution (B) corresponds in position, appearance and intensity with the spot 127 due to 4-toluenesulfonic acid in the chromatogram obtained with solution (D). 128 A 5 mg/mL solution of the test substance yields reaction A described under 2.1 F. 129 General identification tests as characteristic of sulfate. 130 **Sulfate.** 3.5 % to 5.0 % calculated with reference to the anhydrous substance. 131 Dissolve 0.250 g of the test substance in 100 mL of distilled water R and adjust the 132 solution to pH 11 using concentrated ammonia R. Add 10.0 mL of barium chloride 133 (0.1 mol/L) VS and about 0.5 mg of phthalein purple R. Titrate with disodium edetate 134 (0.1 mol/L) VS, adding 50 mL of ethanol (~750 g/L) TS when the colour of the 135 solution begins to change and continue the titration until the violet-blue colour 136 disappears. 1 mL of 0.1 M barium chloride is equivalent to 9.606 mg of SO₄. 137 Water. Determine as described under 2.11 Micro determination of water by the Karl 138 Fischer method. Spread the test substance evenly on a petri dish and let its water 139 content equilibrate for 3 hours under controlled temperature and humidity conditions 140 (see also under "Assay"). Then determine the water content using 60.0 mg of the 141 equilibrated test substance: it is not less than 110 mg/g and not more than 150 mg/g. 142 **Sulfated ash** (2.3, Method B). Not more than 1.0 mg/g, determined on 1 to 2 g. 143 **Heavy metals.** Use 1.000 g for the preparation of the test solution as described under 144 2.2.3 Limit test for heavy metals, Procedure 3. Determine the heavy metals content 145 according to Method B; not more than 20 µg/g. 146

- 147 **Related substances**. Carry out the test as described under 1.14.1 Chromatography,
- High-performance liquid chromatography, using a stainless-steel column (2.1 mm
- 149 x 15 cm) packed with particles of silica gel, the surface of which has been modified
- with chemically bonded octadecylsilyl groups $(1.6 \,\mu\text{m})$.¹
- Prepare a 0.2% trifluoroacetic acid solution by diluting 2.0 mL of trifluoroacetic
- acid R to 1000.0 mL with water R.
- 153 Use the following conditions for gradient elution:
- mobile phase A: a mixture of 0.2% trifluoroacetic acid solution and
- acetonitrile R (97:3 V/V);
- mobile phase B: acetonitrile R.

Time (minutes)	Mobile phase A (% V/V)	Mobile phase B (% V/V)	Comments
0-0.5	100	0	Isocratic
0.5–4.0	100 to 89	0 to 11	Linear gradient
4.0–9.0	89	11	Isocratic
9.0–30.0	89 to 62	11 to 38	Linear gradient
30.0–31.0	62 to 100	38 to 0	Return to initial composition
31.0–40.0	100	0	Re-equilibration

- Operate with a flow rate of 0.3 mL per minute. Maintain the column temperature
- at 35°C and the autosampler at 5°C. As a detector, use an ultraviolet
- spectrophotometer set at a wavelength of 261 nm.
- Prepare the following solutions:

¹ A Waters CORTECS UPLC T3 has been found suitable.

- Sodium dihydrogen phosphate solution (0.05 mol/L): dissolve 7.80 g of
 sodium dihydrogen phosphate dihydrate R in water R to dilute to 1000 mL
 with the same solvent.
- Disodium hydrogen phosphate solution (0.05 mol/L): dissolve 7.098 g of
 anhydrous disodium hydrogen phosphate R in water R and dilute to 1000
 mL with the same solvent.
- Phosphate buffer solution (5 mmol/L): prepare a mixture of water R,
 sodium dihydrogen phosphate solution (0.05 mol/L), and disodium
 hydrogen phosphate solution (0.05 mol/L) (18:1:1 V/V/V).
- Use as a diluent a mixture of phosphate buffer solution (5 mmol/L) and acetonitrile R (9:1 V/V).
- For solution (1), transfer 40 mg of the test substance into a 25 mL volumetric
- flask, dissolve in diluent and dilute to volume with the same diluent.
- For solution (2), dilute 1.0 mL of solution (1) to 100.0 mL with diluent.
- For solution (3), dilute 3.0 mL of solution (2) to 100.0 mL with the diluent.
- For solution (4), transfer 32 mg of cefiderocol sulfate tosilate RS into a 20 mL
- volumetric flask, dissolve in diluent and dilute to volume with the same diluent.
- Heat the obtained solution at 50 °C for 20 minutes and cool to room temperature.
- Inject 2 μ L each of solutions (1), (2), (3) and (4).
- Use the chromatogram obtained with solution (4) to identify the peaks due to 4-
- toluenesulonic acid, and the impurities A, B, C, E and G.
- In the chromatogram obtained with solution (1), the impurities are eluted, if present, at
- the following relative retentions with reference to cefiderocol (retention time about 10
- minutes): 4-toluenesulfonic acid about 0.40; impurity A about 0.45; impurity B about
- 0.61; impurity C about 0.76; impurity F about 0.83, impurity D about 1.23, impurity E

about 1.28, and impurity G about 1.83. The test is not valid unless, in this
chromatogram obtained with solution (4), the resolution between the peaks due to 4toluenesulfonic acid and impurity A is at least 1.5. Also, the test is not valid unless, in
the chromatogram obtained with solution (3), the peak due to cefiderocol is obtained
with a signal-to-noise ratio of at least 20. In the chromatogram obtained with
solution (1):

- the area of any peak corresponding to impurity A, when multiplied with a correction factor of 2.4, is not greater than 0.1 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.10 %);
- the area of any peaks corresponding to impurities C or E are not greater than 0.1 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.10 %);
- the area of any peak corresponding to impurity B, when multiplied with a correction factor of 0.72, is not greater than 0.05 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.05 %);
- the area of any peak corresponding to impurity G, when multiplied with a correction factor of 1.6, is not greater than 0.05 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.05 %);
- the area of any other impurity peak is not greater than 0.05 times the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (0.05 %).
- The sum of the areas of all impurity peaks, including the corrected areas of any peaks corresponding to impurities A, B and G, is not greater than the area of the peak due to cefiderocol in the chromatogram obtained with solution (2) (1.0 %). Disregard all peaks with an area of less than the area of the peak due to cefiderocol in the chromatogram obtained with solution (3) (0.03 %) and any peak due to 4-toluenesulfonic acid.

Assay. Carry out the test as described under 1.14.1 Chromatography, High-213 performance liquid chromatography, using a stainless-steel column (4.6 mm x 10 214 cm) packed with particles of silica gel, the surface of which has been modified with 215 chemically bonded octadecylsilyl groups (3 µm).² 216 Prepare a 0.1% trifluoroacetic acid solution by diluting 1.0 mL of trifluoroacetic 217 acid R to 1000.0 mL with water R. 218 As the mobile phase, use a mixture of 0.1% trifluoroacetic acid solution and 219 acetonitrile (86:14 V/V). 220 Operate with a flow rate of 1.0 mL per minute. Maintain the column temperature 221 at 35°C and the autosampler at 5°C. Use an ultraviolet spectrophotometer set at a 222 wavelength of 261 nm. 223 Prepare the following solutions: 224 Sodium dihydrogen phosphate solution (0.05 mol/L): dissolve 7.80 g of 225 sodium dihydrogen phosphate dihydrate R in water R and dilute to 1000 mL 226 with the same solvent. 227 Disodium hydrogen phosphate solution (0.05 mol/L): dissolve 7.098 g of 228 anhydrous disodium hydrogen phosphate R in water R and dilute to 1000 229 mL with the same solvent. 230 Phosphate buffer solution (5 mmol/L): prepare a mixture of water R, 231 sodium dihydrogen phosphate solution (0.05 mol/L), and disodium 232 hydrogen phosphate solution (0.05 mol/L) (18:1:1 V/V/V). 233 Use as a diluent a mixture of phosphate buffer solution (5 mmol/L) and 234

acetonitrile R (9:1 V/V).

235

² Unison UK-C18 column has been found suitable.

For solution (1), spread the test substance evenly on a petri dish and let its water 236 content equilibrate for 3 hours under the same temperature and humidity 237 conditions used for the determination of its water content, as described under 238 "Water". Then transfer 40.0 mg of the equilibrated test substance into a 25 mL 239 volumetric flask, dissolve in diluent and dilute to volume with the same diluent. 240 Dilute 5.0 mL to 50.0 mL with the diluent. 241 For solution (2), transfer 40.0 mg of cefiderocol sulfate tosilate RS into a 25 mL 242 volumetric flask, dissolve in diluent and dilute to volume with the same diluent. 243 Dilute 5.0 mL to 50.0 mL with the diluent. 244 Inject 10 µL each of solutions (1) and (2) and record the chromatograms for 20 245 minutes. In the chromatograms obtained, the substances are eluted in the order: 4-246 toluenesulfonic acid, cefiderocol. 247 Measure the areas of the peaks corresponding to cefiderocol obtained in the 248 chromatograms of solutions (1) and (2) and calculate the percentage content of 249 3C₃₀H₃₄ClN₇O₁₀S₂·4C₇H₈O₃S·H₂SO₄ in the sample using the declared content of 250 cefiderocol (C₃₀H₃₄ClN₇O₁₀S₂) in cefiderocol sulfate tosilate RS. Each mg of 251 $C_{30}H_{34}ClN_7O_{10}S_2$ corresponds to 1.349 mg of $3C_{30}H_{34}ClN_7O_{10}S_2 \cdot 4C_7H_8O_3S \cdot H_2SO_4$. 252 **Bacterial endotoxins.** If intended for use in the manufacture of a parenteral dosage 253 form without a further appropriate procedure for the removal of bacterial endotoxins, 254 carry out the test as described under 3.4 Test for bacterial endotoxins; contains not 255 more than 0.054 IU of endotoxin per mg of the test substance. 256 **Sterility.** If intended for use in the manufacture of either a parenteral or other sterile 257 258 dosage form without a further appropriate sterilization procedure, complies with 3.2

259

Test for sterility.

260 **Impurities**

261

264

266

268

272

A. 2-Chloro-3,4-dihydroxy-*N*-[2-(pyrrolidin-1-yl)ethyl]benzamide (degradation product)

$$H_3C$$
 CO_2H
 N
 N
 CHO

265 B. 2-{[(Z)-{1-(2-Amino-1,3-thiazol-4-yl)-2-oxo-2-[(2-

oxoethyl)amino]ethylidene}amino]oxy}-2-methylpropanoic acid (degradation

product)

$$H_3C$$
 CO_2H
 CO_2
 CO_2

269 C. (6R,7R)-7-[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2- $\{[(2-carboxypropan-2-yl)$ -2-(2-Amino-1,3-thiazol-4-yl)-2-(2-Carboxypropan-2-yl)-2-(2-Carb

270 yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-

dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-5,8-dioxo-5λ4-thia-1-

azabicyclo[4.2.0]oct-2-ene-2-carboxylate (process related impurity and

273 degradation product)

$$\begin{array}{c|c} H_3C & CO_2H & CO_2^- \\ \hline \\ H_2N & S & O \end{array}$$

275 D. (6R,7S)-7-[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2- $\{[(2$ -carboxypropan-2-yl)-2-(2-Amino-1,3-thiazol-4-yl)-2-(2-Amino-1,3-thiazol-4-yl)-2-(2-Carboxypropan-2-yl)-2-(2

276 yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-

dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-8-oxo-5-thia-1-

azabicyclo[4.2.0]oct-2-ene-2-carboxylate (process related impurity, degradation

product)

274

278

280

282

284

281 E. (

E. (6R,7R)-7-[(2E)-2-(2-Amino-1,3-thiazol-4-yl)-2- $\{[(2$ -carboxypropan-2-

yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-

dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-8-oxo-5-thia-1-

azabicyclo[4.2.0]oct-2-ene-2-carboxylate (process related impurity, degradation

product)

$$\begin{array}{c|c} H_3C & CO_2H & CO_2^- \\ H_3C & O & H \\ \hline \\ H_2N & O & H \\ \end{array}$$

286

287

F. [chemical name to be added at a later stage] (process related impurity and

degradation product)

289

290

291

292

293

294

295

G. (6*R*,7*R*)-7-[(2*Z*)-2-(2-Amino-5-{[(2*R*)-2-{(*R*)-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido](carboxy)methyl}-4-carboxy-3,6-dihydro-2*H*-1,3-thiazin-5-yl]methyl}-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido]-3-({1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (degradation product)

296

297

- Reference substances to be established.
- 298 Cefiderocol sulfate tosilate RS
- New International Chemical Reference Substance to be established.
- 300 Reagents to be revised.
- 301 4-Toluenesulfonic acid R
- 4-Methylbenzenesulfonic acid, C₇H₈O₃S, H₂O.
- 303 *Content*: minimum 87.0 % of C₇H₈O₃S.
- 304 *Description*: White or almost white, crystalline powder or crystals, freely soluble in 305 water, soluble in Ethanol (~750 g/L) TS.

306

307 ***